Emmanuel Quaye
Internal Medicine · Lancaster, SCNPI 1043249949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,124 and has fallen 72.1% since, to $314 in 2025.
Across 90 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$407
- AbbVie$284
- Novo Nordisk$218
- Lilly USA, LLC$200
- Bayer$163
- Amgen$130
- plus $581 from 18 others
What the payments were for
- Food & beverage$1,983100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $407 |
| AbbVie | 15 | $284 |
| Novo Nordisk | 10 | $218 |
| Lilly USA, LLC | 9 | $200 |
| Bayer | 4 | $163 |
| Amgen | 6 | $130 |
| Forte Bio-pharma LLC | 2 | $126 |
| Novartis | 4 | $78 |
| Astellas Pharma US Inc | 2 | $46 |
| Exact Sciences | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Bard Peripheral Vascular, Inc. | 1 | $39 |
| Merck | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Cranial Technologies, Inc | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| GSK | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Abbott | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Corcept Therapeutics | 1 | $12 |
| Vyera Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,983 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 37 | $350 |
| Gabapentin | 19 | $247 |
| ClopidogrelClopidogrel Bisulfate | 12 | $224 |
| Tamsulosin Hcl | 11 | $139 |
| Amlodipine Besylate | 21 | $124 |
| Lisinopril | 13 | $117 |
| Losartan Potassium | 15 | $98 |
| Meloxicam | 18 | $61 |
| Metformin Hcl | 18 | $58 |
| Pantoprazole Sodium | 13 | $50 |
| Hydrochlorothiazide | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Lancaster
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
- Lisa DarbyGreenville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.